Clinical Trials Directory

Trials / Withdrawn

WithdrawnNCT05014061

Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction

Adenosine's Effect on STunning Resolution in Acute Myocardial Infarction An Open-label, Single Center Trial

Status
Withdrawn
Phase
Phase 3
Study type
Interventional
Enrollment
0 (actual)
Sponsor
Vastra Gotaland Region · Other Government
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The aim of this study is to evaluate the effect of adenosine on the recovery of myocardial akinesia in ST-elevation myocardial infarction (STEMI). The study is a single-center randomized clinical trial intending to include 90 patients. The objective of the study is to investigate whether treatment with adenosine hastens recovery of myocardial akinesia and improves cardiac function at 48 hours in patients with STEMI.

Detailed description

Primary endpoint (variable): The resolution of myocardial stunning at 48 hours (StunningRes48h). The proportion of stunning that has resolved at 48 hours will be calculated according to the formula: StunningRes48h = (%AkinesiaBaseline - %Akinesia48h) / (%AkinesiaBaseline - %Akinesia30days) where %AkinesiaT is defined as the endocardial length of the akinetic myocardium measured in end-diastole divided by the total endocardial length measured in end-diastole in the 2- and 4-chamber view, at time T (T= 48h or 30 days) Secondary endpoint(s) (variables): 1. Infarct size at 6 months, as assessed by cardiac magnetic resonance imaging (magnetic resonance imaging). 2. Ejection fraction days 1, 2, 3, 7, 14, 30 and 6 months. 3. Any sustained ventricular tachycardia or fibrillation within 72 hours (safety endpoint; binary) 4. Any high-grade atrioventricular block or sinus arrest within 72 hours (safety endpoint; binary) 5. Implantation of cardiac assist device within 72 hours (binary) 6. Stroke within 6 months (binary) 7. All-cause mortality within 6 months 8. Heart failure rehospitalization within 6 months\* 9. Worsening in-hospital heart failure ≥12 hours after PCI# 10. Composite of any worsening in-hospital heart failure ≥12 hours after PCI or heart failure rehospitalization within 6 months. * Defined as re-admission to hospital after discharge, with a total length of admission ≥24 hours, documented worsening of heart failure signs or symptoms (e.g. worsening dyspnea, fatigue, edema/fluid overload, pulmonary venous distension or signs of pulmonary edema on X-ray), with administration of intravenous diuretic or inotropic drugs, ultrafiltration, non-invasive ventilation or mechanical assist device. * Defined as intensification of heart failure therapy due to worsening heart failure signs or symptoms (as above; including intravenous diuretic, inotropic or vasopressor drugs, non-invasive ventilation or mechanical assist device).

Conditions

Interventions

TypeNameDescription
DRUGAdenosineAdenosine infusion 70 µg/kg/min for 6 hours

Timeline

Start date
2023-01-01
Primary completion
2025-06-01
Completion
2025-12-01
First posted
2021-08-20
Last updated
2024-05-17

Source: ClinicalTrials.gov record NCT05014061. Inclusion in this directory is not an endorsement.